These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19670957)

  • 41. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
    Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
    Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
    Trish E; Xu J; Joyce G
    Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.
    Dusetzina SB; Huskamp HA; Keating NL
    JAMA; 2019 May; 321(20):2025-2027. PubMed ID: 31135837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
    Glynn A; Hernandez I; Roberts ET
    Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
    Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
    Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
    Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
    Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.
    Polinski JM; Shrank WH; Huskamp HA; Glynn RJ; Liberman JN; Schneeweiss S
    PLoS Med; 2011 Aug; 8(8):e1001075. PubMed ID: 21857811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association Between Prescription Drug Insurance and Health Care Utilization Among Medicare Beneficiaries.
    Alexander GC; Schiman C; Kaestner R
    Med Care Res Rev; 2018 Apr; 75(2):153-174. PubMed ID: 29148319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of coding intensity in Medicare Advantage on plan benefits and finances.
    Jacobs PD; Kronick R
    Health Serv Res; 2021 Apr; 56(2):178-187. PubMed ID: 33165932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sources of regional variation in Medicare Part D drug spending.
    Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
    N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.
    Kennedy J; Dipzinski A; Roll J; Coyne J; Blodgett E
    Drug Alcohol Depend; 2011 Apr; 114(2-3):201-6. PubMed ID: 21134724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government.
    Trish E; Kaiser KM; Celestin J; Joyce G
    J Health Polit Policy Law; 2022 Dec; 47(6):853-877. PubMed ID: 35867529
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
    Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
    BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
    Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
    J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Take-up of Medicare Part D: results from the Health and Retirement Study.
    Levy H; Weir DR
    J Gerontol B Psychol Sci Soc Sci; 2010 Jul; 65(4):492-501. PubMed ID: 20034992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance program.
    Bishop CE; Ryan AM; Gilden DM; Kubisiak J; Thomas CP
    Health Serv Res; 2009 Jun; 44(3):1010-28. PubMed ID: 19291168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
    Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
    Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11.
    Trish E; Joyce G; Goldman DP
    Health Aff (Millwood); 2014 Nov; 33(11):2018-24. PubMed ID: 25367998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvements in Medicare Part D risk adjustment: beneficiary access and payment accuracy.
    Kautter J; Ingber M; Pope GC; Freeman S
    Med Care; 2012 Dec; 50(12):1102-8. PubMed ID: 22922436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.